Another exciting point to note from the Investor presentation is one of the final slides Dr Mor presented. That slide showed dosages of 0.1ug/ml killed cancer "even faster" when used with increased Fas levels.
Basically that means that they don't even need to ramp up the dosage levels and that the death receptor drug should enable Phenoxodiol to achieve "total kill" of cancer, even in those 30-40% of cancers that present no significant levels of death receptors.
Very exciting indeed.
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
